Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct:8:45-53.
doi: 10.1016/j.coviro.2014.06.002. Epub 2014 Jul 2.

Antiviral drugs specific for coronaviruses in preclinical development

Adeyemi O Adedeji  1 , Stefan G Sarafianos  2
Affiliations
Review

Antiviral drugs specific for coronaviruses in preclinical development

Adeyemi O Adedeji et al. Curr Opin Virol. 2014 Oct.

Abstract

Coronaviruses are positive stranded RNA viruses that cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses impeded the development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV), and more recently, Middle East respiratory syndrome coronavirus (MERS-CoV), has impelled the development of such drugs. This review focuses on some newly identified SARS-CoV inhibitors, with known mechanisms of action and their potential to inhibit the novel MERS-CoV. The clinical development of optimized versions of such compounds could be beneficial for the treatment and control of SARS-CoV, the current MERS-CoV and other future SARS-like epidemics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Names and chemical structures of examples of SARS-CoV 3CLP and PLP protease inhibitors.
Figure 2
Figure 2
Names and chemical structures of examples of SARS-CoV helicase inhibitors.
Figure 3
Figure 3
Model for the different stages of SARS-CoV entry that are potential antiviral targets.
Figure 4
Figure 4
Examples of SARS-CoV entry inhibitors.
See this image and copyright information in PMC

References

    1. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820. - PubMed
    1. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300:1394–1399. - PubMed

    2. This is the first report for the complete sequence of SARS-CoV complete genome with phylogenetic analyses and sequence comparisons indicating its novelty.

    1. Thiel V., Herold J., Schelle B., Siddell S.G. Viral replicase gene products suffice for coronavirus discontinuous transcription. J Virol. 2001;75:6676–6681. - PMC - PubMed
    1. Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S., Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W. Mechanisms and enzymes involved in SARS coronavirus genome expression. J Gen Virol. 2003;84:2305–2315. - PubMed
    1. Narayanan K., Maeda A., Maeda J., Makino S. Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells. J Virol. 2000;74:8127–8134. - PMC - PubMed

Publication types

MeSH terms

Substances